Antisense oligonucleotides targeted to il-15
CA 2332699 A1 · Owner: Hamanaka, Shoji · Inventors: Hamanaka, Shoji; Hiroyuki, Kubo; Nozawa, Iwao
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention features antisense oligonucleotide molecules that specifically bind polynucleotides encoding IL-15. The present invention provides antisense oligonucleotides capable of inhibiting IL-15 expression and methods of use , thereof to reduce activity of IL-15 in tissues in order to treat diseases such as rheumatoid arthritis, inflammatory bowel disease multiple sclerosis, chronic liver disease ulcerative colitis and cell proliferative disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 7, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 7, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 7, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.